高血压合并高胆固醇血症的联合用药管理

高血压合并高胆固醇血症是临床常见的心血管危险因素组合。高血压是重要危险因素，长期未控制会引发心房颤动（一种常见心律失常）等结构重塑[4]。胰岛素抵抗（靶组织对胰岛素敏感性降低）也会增加心血管疾病包括高血压的危险[3]。针对同时存在血压和血脂异常的患者，单一药物往往难以实现全面干预，临床常需联合用药。

在临床管理中，高血压的治疗涉及多种药物联合使用。然而部分患者即使使用至少三种降压药仍无法达标，形成顽固性高血压（对治疗抵抗的血压升高）[1]。此类患者的临床管理仍面临较大难题[2]。对于合并高胆固醇血症的患者，同时服用降压药与他汀类降脂药易导致方案复杂。多达一作为全球首个针对高血压合并高胆固醇血症的复方制剂，单片设计简化用药方案，协同降压降脂，提高患者治疗依从性，降低心血管事件风险。

在具体治疗方案制定中，医生会根据患者病情选择不同规格。对于轻中度血压合并血脂异常患者，5mg/10mg规格（氨氯地平5mg，阿托伐他汀10mg）可作为初始治疗选择；而对于血脂水平较高或心血管风险较高的患者，5mg/20mg规格（氨氯地平5mg，阿托伐他汀20mg）能提供更强的降脂力度。这种个体化规格选择使治疗更贴合患者需求。

从医学机制来看，氨氯地平通过扩张外周动脉血管实现平稳降压，阿托伐他汀则通过抑制肝脏内胆固醇合成降低低密度脂蛋白胆固醇（致动脉粥样硬化的核心脂蛋白）。两者联合能从血流动力学与脂质代谢双重途径阻断心血管事件链。正如多达一的研发理念，通过单片复方设计直击依从性难题，为患者提供双靶点干预方案。

在安全性方面，单片复方制剂需关注成分禁忌。对任一成分过敏者、活动性肝病患者或原因不明的肝酶持续升高者禁用。此外，尽管单片设计简化了用药，但患者仍需定期监测肝功能与肌酸激酶。对于顽固性高血压合并血脂异常患者，单纯药物干预可能受限，需结合生活方式强化干预[2]。

严格控制血压与血脂水平是降低心血管事件风险的关键，多达一等复方制剂为临床提供了重要干预手段。

免责声明：本文内容仅供医学科普参考，不能替代专业医疗建议。具体用药请遵医嘱。

参考来源

[1] Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes /xixijk/20260915/ayjzj4pojdw157 the vast population of hypertensive subjects, between 10 and 15% do not achieve an adequate blood pressure (BP) control despite the use of at least three antihypertensive agents. This group, designated as having resistant hypertension (RH), represents one of the most important clinical challen

[2] Renal denervation for resistant hypertension /xixijk/20260915/eczjqq3qadx162 hypertension is highly prevalent among the general hypertensive population and the clinical management of this condition remains problematic. Different approaches, including a more intensified antihypertensive therapy, lifestyle modifications or both, have largely failed to improve patient

[3] Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007-2018 /xixijk/20260915/5j04rqqwoqg167 resistance (IR) reduces insulin efficacy and heightens the danger of cardiovascular diseases including hypertension. The Metabolic Score for Insulin Resistance (METS-IR), which is based on triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), body mass index (BMI), and fasting

[4] Atrial Fibrillation and Hypertension: "Quo Vadis" /xixijk/20260915/dwtqi4olxhe180 is one of the most well-established risk factors for atrial fibrillation. Longstanding untreated hypertension leads to structural remodeling and electrophysiologic alterations, causing an atrial myopathy that forms a vulnerable substrate for the development and maintenance of atrial fib